Oliceridine and its potential to revolutionize GI endoscopy sedation

Area of Science:

• Anesthesiology
• Gastroenterology
• Pharmacology

Background:

• Sedation for gastrointestinal (GI) endoscopy is controversial, with propofol being the standard but requiring anesthesia provider administration.
• Previous attempts to broaden sedation authority, like fospropofol and Sedasys, faced limitations due to safety concerns or efficacy.
• Remimazolam presents a potential alternative but has unaddressed issues with respiratory depression and failure rates.

Purpose of the Study:

• To explore novel pharmacologic approaches for safe and effective sedation in GI endoscopy.
• To evaluate the potential of G protein-biased μ-receptor agonists, specifically oliceridine, as an adjunct or alternative to current sedation methods.

Main Methods:

• Review of existing literature and drug profiles for sedation agents in GI endoscopy.
• Analysis of the pharmacological properties of G protein-biased μ-receptor agonists, focusing on oliceridine's safety and efficacy profile.
• Comparison of oliceridine's effects with propofol, fentanyl, midazolam, and remimazolam regarding respiratory depression and procedural success.

Main Results:

• Oliceridine, a G protein-biased μ-receptor agonist, demonstrates analgesic properties similar to morphine but with reduced respiratory depression.
• Oliceridine can be used adjunctively with midazolam or remimazolam, enabling comfortable colonoscopies without propofol.
• For anesthesia providers, oliceridine may eliminate the need for fentanyl, mitigating additive respiratory depression.

Conclusions:

• Oliceridine presents a promising option for safe and cost-effective sedation in GI endoscopy.
• This new class of opioids has the potential to improve patient safety and procedural efficiency.
• Further research may confirm oliceridine's role in optimizing sedation protocols for endoscopic procedures.